A Phase 2 Trial Testing ZP1848 in Patients With SBS

Trial Profile

A Phase 2 Trial Testing ZP1848 in Patients With SBS

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Mar 2018

At a glance

  • Drugs Glepaglutide (Primary)
  • Indications Short bowel syndrome
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Zealand Pharma
  • Most Recent Events

    • 07 Mar 2018 According to a Zealand Pharma media release, data from the trial was presented at the ASPEN conference 2018.
    • 23 Jan 2018 According to a Zealand Pharma media release, more detailed results from the trial focusing on micro- and macronutrients, intestinal morphology and intestinal transit time will be presented at further scientific conferences in 2018.
    • 23 Jan 2018 Results published in a Zealand Pharma Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top